Clinical Trial

ClearSight NextGen1 Study

Completed
View on ClinicalTrials.gov →
Summary
A prospective, non-randomized single arm study using the investigational ClearSight NextGen (CSNG) system in adult subjects.
Protocol Amendment History 4 changes
critical Trial completed 2026-04-09
critical Phase changed: not specified -> not applicable 2026-04-09
notable Enrollment increased: 30 -> 35 participants 2026-04-09
minor Completion moved earlier: 2026-05 -> 2026-03-05 2026-04-09
Trial Details
NCT Number NCT07317648
Lead Sponsor Becton, Dickinson and Company
Conditions Blood Pressure
Enrollment 35 participants
Start Date 2025-10-16
Primary Completion 2026-03-05 (estimated)
Study Completion 2026-03-05 (estimated)
Updated on ClinicalTrials.gov 2026-07-08